Literature DB >> 21789085

The value of prostate-specific antigen in Asia.

Chaidir Arif Mochtar1, R Siddhi Andika.   

Abstract

One of the most important diagnostic tools used to detect prostate cancer is prostate-specific antigen (PSA), yet increased PSA alone does not reflect the presence of prostate cancer. Other pathological prostatic conditions such as prostatitis and benign prostatic hyperplasia (BPH) may also increase the level of PSA. However, unlike in other prostate diseases, PSA has a key role in the diagnosis and management of prostate cancer. The incidence of prostate cancer varies from country to country, with the highest incidence being found in the Western world and the lowest in Asian countries. Owing to the low incidence of prostate cancer, there could be different views regarding the use of PSA in Asian countries, especially for the early detection/screening of prostate cancer. The purpose of this article is to review the use and value of PSA in the diagnosis of prostate diseases (especially prostate cancer) in Asian countries/populations. A literature search was performed in 'MEDLINE' (PubMed) and Google Scholar using main keywords such as 'PSA', 'PSA usage', 'PSA sensitivity and specificity', 'Asia', and various countries in Asia. Articles that provide population/community-based PSA data, together with the characteristics, distribution, and indications for PSA testing in the respective countries, were selected. Eleven papers were finally selected for inclusion in this review. Five studies found that PSA, by its 95th percentile value, have an age-referenced tendency in Asian males, similarly to the West. The predictive values of PSA in detecting prostate cancer are also quite similar to those in Western countries. With the exponential growth of the aging population in the world, especially in Asia, the incidence of prostate cancer will follow this upward trend. Therefore, PSA testing for screening or diagnostic purposes would increase with time in Asia.

Entities:  

Keywords:  predictive value; prostate cancer; prostate-specific antigen; screening

Year:  2010        PMID: 21789085      PMCID: PMC3126072          DOI: 10.1177/1756287210370329

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  32 in total

1.  New NHS guidelines for PSA testing in primary care.

Authors:  Robin Weston; Nigel Parr
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

2.  Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score.

Authors:  Y Homma; K Kawabe; T Tsukamoto; H Yamanaka; K Okada; E Okajima; O Yoshida; J Kumazawa; F L Gu; C Lee; T C Hsu; R C dela Cruz; A Tantiwang; P H Lim; M A Sheikh; S D Bapat; V R Marshall; K Tajima; Y Aso
Journal:  Int J Urol       Date:  1997-01       Impact factor: 3.369

3.  Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA).

Authors: 
Journal:  Oncology (Williston Park)       Date:  2000-02       Impact factor: 2.990

4.  Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen.

Authors:  Hong-Wen Gao; Yu-Lin Li; Shan Wu; Yi-Shu Wang; Hai-Feng Zhang; Yu-Zhuo Pan; Ling Zhang; Hiroo Tateno; Ikuro Sato; Masaaki Kuwahara; Xue-Jian Zhao
Journal:  Asian J Androl       Date:  2005-06       Impact factor: 3.285

5.  The clinical usefulness of prostate-specific antigen (PSA) level and age-specific PSA reference ranges for detecting prostate cancer in Chinese.

Authors:  Tony T Wu; Jong-Khing Huang
Journal:  Urol Int       Date:  2004       Impact factor: 2.089

6.  Prostate-specific antigen levels among Chinese, Malays and Indians in Singapore from a community-based study.

Authors:  Sin-Eng Chia; Weber Ko Lau; Christopher Cheng; Chong Min Chin; James Tan; Siew Hong Ho
Journal:  Asian Pac J Cancer Prev       Date:  2007 Jul-Sep

7.  Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects.

Authors:  Robert A Smith; Vilma Cokkinides; Harmon J Eyre
Journal:  CA Cancer J Clin       Date:  2007 Mar-Apr       Impact factor: 508.702

8.  A prospective study of dietary fat and risk of prostate cancer.

Authors:  E Giovannucci; E B Rimm; G A Colditz; M J Stampfer; A Ascherio; C G Chute; C C Chute; W C Willett
Journal:  J Natl Cancer Inst       Date:  1993-10-06       Impact factor: 13.506

Review 9.  Diet and prostate cancer.

Authors:  Tomoyuki Shirai; Makoto Asamoto; Satoru Takahashi; Katsumi Imaida
Journal:  Toxicology       Date:  2002-12-27       Impact factor: 4.221

10.  The routine use of prostate-specific antigen for early detection of cancer prostate in India: Is it justified?

Authors:  Deepak Dubey
Journal:  Indian J Urol       Date:  2009-04
View more
  5 in total

Review 1.  Demography and disease characteristics of prostate cancer in India.

Authors:  Krishnamoorthy Hariharan; Venugopal Padmanabha
Journal:  Indian J Urol       Date:  2016 Apr-Jun

Review 2.  Multiparametric MRI in Active Surveillance of Prostate Cancer: An Overview and a Practical Approach.

Authors:  Chau Hung Lee; Teck Wei Tan; Cher Heng Tan
Journal:  Korean J Radiol       Date:  2021-04-01       Impact factor: 3.500

3.  Effects of 14 frequently used drugs on prostate-specific antigen expression in prostate cancer LNCaP cells.

Authors:  Kazuhiro Iguchi; Maki Hashimoto; Masafumi Kubota; Shuji Yamashita; Mitsuhiro Nakamura; Shigeyuki Usui; Tadashi Sugiyama; Kazuyuki Hirano
Journal:  Oncol Lett       Date:  2014-03-05       Impact factor: 2.967

4.  The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men.

Authors:  Jeremy Yc Teoh; Steffi Kk Yuen; James Hl Tsu; Charles Kw Wong; Brian Sh Ho; Ada Tl Ng; Wai-Kit Ma; Kwan-Lun Ho; Ming-Kwong Yiu
Journal:  Asian J Androl       Date:  2017 Jan-Feb       Impact factor: 3.285

5.  Current and Future Burden of Prostate Cancer in Songkhla, Thailand: Analysis of Incidence and Mortality Trends From 1990 to 2030.

Authors:  Christian S Alvarez; Shama Virani; Rafael Meza; Laura S Rozek; Hutcha Sriplung; Alison M Mondul
Journal:  J Glob Oncol       Date:  2018-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.